Hypertrophic adipocytes undergo phenotypic changes and begin to secrete inflammatory adipokines (bioactive molecules released from an adipocyte) and cytokines (immune signaling molecules involved in inflammation, immunity, and cell communication)
GLP-1s open a door, but lasting health comes from how we walk through it guided by sleep, calm, purpose, and connection. Dive into our GLP-1 resource center for stories on weight loss, medications, side effects, and more
Viking Therapeutics - VK2735 (oral, dual GLP1/GIP agonist) Viking Therapeutics is actively developing VK2735, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, with both subcutaneous and oral formulations in its pipeline
Understanding the differences matters